DOCSLIB.ORG

Eprocurement Small Order Process: Vendors with Item Catalogs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Eprocurement Small Order Process: Vendors with Item Catalogs eProcurement Small Order Process: Vendors with Item Catalogs Updated April 18, 2012 V000142495 ABCAM INC V000137051 ILLUMINA INC V000081265 ACO MEDICAL SUPPLY V000014509 INTERMOUNTAIN SCIENTIFIC V000125369 ACTIVE MOTIF V000080847 INTREX COMPUTERS INC V000112094 AFFYMETRIX INC V000006118 INVITROGEN CORPORATION V000114793 AGILENT TECHNOLOGIES INC V000130596 INVIVOGEN V000000082 ALLTECH ASSOCIATES INC V000005714 JACKSON IMMUNORES V000000118 AMRESCO V000001442 JACKSON LAB V000152997 ANASPEC INC V000001558 LABORATORY SAFETY V000132756 ASYLUM RESEARCH CORP V000047258 LABREPCO INC V000000126 ATCC V000108167 LEICA MICROSYSTEMS V000068824 ATLANTA BIOLOGICALS V000088788 LI-COR INC V000162435 ATLANTIC FITNESS V000111733 LIST BIOLOGICAL LABS V000000307 BASI V000002832 LONZA WALKERSVILLE INC V000000261 BD BIOSCIENCES V000149811 MATRIX TECH V000000259 BECKMAN COULTER V000135360 MEDICAL SPECIALTIES V000176191 BENCHMARK TECH V000022962 MIDWEST SCIENTIFIC V000101618 BETHYL LABS V000078901 MILTENYI BIOTEC INC V000159330 BIO BASIC V000008542 MOLECULAR DEVICES INC V000004901 BIOGENIX LABORATORIES V000001340 MP BIOMEDICALS V000145647 BIOLEGEND V000188293 NETA SCIENTIFIC INC V000157241 BIOLINE USA INC V000186184 NEWEAST BIOSCIENCES V000112934 BIOLOGICAL SPECIALTY CORP V000001880 NEW ENGLAND BIOLABS INC V000000303 BIO-RAD V000004850 NEWPORT V000000305 BIO-TEK INSTRUMENTS V000052248 NIKON INSTRUMENTS INC V000000349 BRAINTREE V000167597 OCEAN OPTICS V000190375 BUTLER SCHEIN V000001937 OLYMPUS AMERICA INC V000000429 CAMCOR V000139707 OPEN BIOSYSTEMS V000000454 CAROLINA BIOLOGICAL V000062559 PEPROTECH INC V000007795 CAYMAN CHEMICAL V000157880 PEPSI V000120542 CELL SIGNALING TECHNOLOGY V000103947 PHENIX V000161374 CH INSTRUMENTS INC V000002055 PIERCE BIOSYSTEMS V000015692 CHEMGLASS LIFESCIENCES V000002074 POLYSCIENCES INC V000006376 CLONTECH V000002108 PROMEGA CORPORATION V000004686 COCA-COLA V000015625 QIAGEN V000091909 COVANCE RESEARCH PRODUCTS V000005698 R&D SYSTEMS INC V000173188 CREOSALUS V000002157 RAININ INSTRUMENT LLC V000029248 DAKO NORTH AMERICAN V000125143 RESEARCH DIETS V000000795 DENVILLE SCIENTIFIC INC V000000331 ROCHE DIAGNOSTICS V000000754 DRACOR INC V000116472 SANOFI PASTEUR V000123388 EBIOSCIENCE INC V000054502 SANTA CRUZ BIOTECHNOLOGY V000000953 ELECTRON MICROSCOPY SCIENCES V000004670 SARSTEDT INC V000006513 EMD MILLIPORE BIOSCIENCES V000177749 SEGUENOM INC V000029734 EPICENTER TECHNOLOGIES CORP V000155986 SENECA MEDICAL V000155552 EPPENDORF V000002343 SHAMROCK SCIENTIFIC V000010522 EUROFINS MWG OPERON V000107920 SIEMENS INDUSTRY V000001037 FINE SCIENCE TOOLS (USA) INC V000007189 SOUTHERN MICROSCOPE V000056795 GEMINI BIOPRODUCTS V000065308 STEM CELL TECHNOLOGIES INC V000118475 GENESEE SCIENTIFIC CORP V000072023 TOCRIS BIOSCIENCE V000167753 GENEWIZ V000115285 TRILINK BIOTECH V000143396 GENSCRIPT USA V000130007 TRITECH RESEARCH INC eProcurement Small Order Process: Vendors with Item Catalogs Updated April 18, 2012 V000093195 GETINGE V000053392 ULINE V000001148 GILSON INC V000002712 USA SCIENTIFIC INC V000001179 GRANVILLE MILLING V000109441 USB CORPORATION V000028937 GREER LABORATORIES INC V000002741 VECTOR V000001218 HAMAMATSU CORP V000002799 WATERS TECHNOLOGIES CORP V000053208 HAMPTON RESEARCH INC V000099869 ZYMO RESEARCH .
Load more

Recommended publications
  • Participant List
    Participant list Please find below a list of current participants in theAustralian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A. Menarini Australia B Braun Avitum Australia Cardinal Health AbbVie Australia Bausch & Lomb (Australia) Cepheid Abbott Australasia Baxter Healthcare Cochlear Acrux Bayer Coloplast Australia Alcon Beckman Coulter - Diagnostics Convatec (Australia) Alere Beckman Coulter - Life Sciences CooperVision Australia Allergan Becton Dickinson DH Dental Alphapharm Besins Healthcare Australia DSM Nutritional Products Amgen Biogen Idec Australia Device Technologies Aust Ascom Australia Biomerieux Australia Ecolab Aspen Australia Blackmores Edwards Lifesciences Astellas Pharma Boehringer Ingelheim Eisai Australia AstraZeneca Boston Scientific International Elanco Australasia Australian Nuclear Science and Technology Boucher & Muir Eli Lilly Australia Organisation (ANSTO) Bristol-Myers Squibb Evolution Health Australian Pharmaceutical Industries CSL Ferring Pharmaceuticals B Braun Australia © September 2020 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 Participant list Fresenius Kabi Australia Integrated DNA Technologies (IDT) Merck Serono Fresenius Medical Care Australia Invisalign Australia Mindray Medical International GE Australia Healthcare Ipsen Molnlycke Health Care GN Netcom Australia J&J Pacific Mundipharma Galderma Australia Janssen-Cilag - Australia Nevro Medical Australia Getinge Johnson & Johnson Medical
    [Show full text]
  • 2017 INVESTOR & ANALYST DAY December 14, 2017
    2017 INVESTOR & ANALYST DAY December 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions, contingent
    [Show full text]
  • Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER
    EN Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 16/06/2011 In electronic form on the EUR-Lex website under document number 32011M6175 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 16.06.2011 C(2011)4423 In the published version of this decision, some information has been omitted pursuant to Article PUBLIC VERSION 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a ARTICLE 6(1)(b) DECISION general description. To the notifying party: Dear Sir/Madam, Subject: Case No COMP/M.6175 - Danaher/ Beckman Coulter Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/20041 1. On 6 May 2011, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Djanet Acquisition Corp. (USA) controlled by Danaher Corporation (USA) ("Danaher") acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Beckman Coulter, Inc. (USA) ("Beckman") by way of public bid announced on 15 February 2011. Danaher and Beckman are designated hereinafter as the "parties (to the proposed transaction)"2. 1 OJ L 24, 29.1.2004, p. 1 ("the Merger Regulation").
    [Show full text]
  • 2018 Annual Report
    2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
    [Show full text]
  • Beckman Coulter Expanding Operations
    NEWS RELEASE Contacts: Hillary Hunter, Public Relations Phone: (561) 714-7826 E-mail: [email protected] Steve Ernst, Veris Communications Phone: (973) 702-7249 E-mail: [email protected] FOR IMMEDIATE RELEASE Beckman Coulter Life Sciences Expands Particle Characterization Group, Adds Hach Company’s Particle Counting Division Combined Businesses to Offer World-Class Expertise, Service and Solutions INDIANAPOLIS – October 21, 2013 – Beckman Coulter Life Sciences announces it is combining its Particle Characterization business with the Particle Counting business from Hach Company. This move brings together Beckman Coulter’s expertise in cell viability, particle sizing and particle analysis with Hach’s prominence in air and liquid particle counting, and will enable deeper particle characterization solutions, world-class customer support and superior service. In some countries the transition is subject to completing consultation and/or information with certain employee representative bodies. “This is an exciting time in the histories of these two storied enterprises,” said Jennifer Honeycutt, president, Beckman Coulter Life Sciences. “The Coulter, MET ONE and HIAC™ brands helped found the particle counting and characterization industry. Bringing them together allows us to continue to build on the success of these businesses and bring tremendous value to our customers.” Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work alongside the Particle Characterization team. Combing these two leading, Danaher Corporation-owned life science companies redefines the Beckman Coulter Particle Characterization business and uniquely positions it to provide innovative technologies to a number of important markets. For more information, please visit www.particle.com.
    [Show full text]
  • Appendices Due to Concerns Over the Quality of the Data Collected
    APPENDIX A WSU 2014-19 STRATEGIC PLAN Appendix A: WSU Strategic Plan 2014-15 Strategic Plan 2014-2019 President Elson S. Floyd, Ph.D. Strategic Plan 2014-2019 Introduction The 2014-19 strategic plan builds on the previous five-year plan, recognizing the core values and broad mission of Washington State University. Goals and strategies were developed to achieve significant progress toward WSU’s aspiration of becoming one of the nation’s leading land-grant universities, preeminent in research and discovery, teaching, and engagement. The plan emphasizes the institution’s unique role as an accessible, approachable research institution that provides opportunities to an especially broad array of students while serving Washington state’s broad portfolio of social and economic needs. While providing exceptional leadership in traditional land-grant disciplines, Washington State University adds value as an integrative partner for problem solving due to its innovative focus on applications and its breadth of program excellence. The plan explicitly recognizes the dramatic changes in public funding that have occurred over the duration of the previous strategic plan, along with the need for greater institutional nimbleness, openness, and entrepreneurial activity that diversifies the University’s funding portfolio. In addition, the plan reaffirms WSU’s land-grant mission by focusing greater attention system-wide on increasing access to educational opportunity, responding to the needs of Washington state through research, instruction, and outreach, and contributing to economic development and public policy. While the new plan retains the four key themes of the previous plan, its two central foci include offering a truly transformative educational experience to undergraduate and graduate students and accelerating the development of a preeminent research portfolio.
    [Show full text]
  • Envista Holdings Corp NVST
    14 October 2019 Equity Research Americas | United States Envista Holdings Corp NVST Bracing for Growth; Initiate Neutral; $30 Target Price Target price (12M, US$) 30.00 [V] Life Science Tools and Diagnostics | Initiation Neutral ■ Initiate Neutral; $30 Target Price: As a leading global manufacturer of dental, NVST is Price (11 Oct 19, US$) 27.93 levered to a seemingly stabilizing underlying dental industry backdrop, where it supports 52-week price range 29.07 - 26.59 90% of practitioners’ clinical needs. We expect earnings growth to accelerate on dedicated Market cap (US$ m) 4,431.13 innovation efforts, greater penetration in high-growth markets, and efficiency initiatives as a Enterprise value (US$ m) 5,650.91 [V] = Stock Considered Volatile (see Disclosure Appendix) more nimble standalone entity, as the recent spinoff of Danaher’s Dental segment. All in, these drivers should accelerate organic revenue growth to +low to mid-single digits over the next five years, with earnings growing at a +7% CAGR from 2019E-2023E. Research Analysts ■ Positioning for Growth via Targeted Innovation: While dental demand trends have Erin Wilson Wright been lackluster over the past few years, we view rising dental utilization stemming from 212 538 4080 favorable demographics, an emphasis on aesthetic and preventative care, along with [email protected] expanding adoption of digital dentistry should drive improving demand for dental Katie Tryhane consumables and equipment long term. For NVST, reinvigorated innovation, focused on 212 325 2713 Specialty products (i.e. N1 Implants, Spark Clear Aligners), an inherently faster growing [email protected] category (48% of sales), should spur growth, alongside efforts to fortify Dental Support Org.
    [Show full text]
  • 2012 Annual Report 1 Table of Contents
    2012 ANNUAL REPORT 1 TABLE of CONTENTS Environmental 2 Test & Measurement 4 Dental 6 Life Sciences & Diagnostics 8 Industrial Technologies 10 Letter to the Shareholders 12 2012 Form 10-K 16 Supplemental Financial Information 141 Directors & Executive Officers 143 Shareholder Information 144 DANAHER FINANCIAL OPERATING HIGHLIGHTS (dollars in millions, except per share data and number of associates) 2012 2011 Sales* $ 18,260.4 $ 16,090.5 Operating Profit* $ 3,165.1 $ 2,617.2 Net Earnings* $ 2,299.3 $ 1,935.3 Earnings per share (diluted)* $ 3.23 $ 2.77 Operating Cash Flow* $ 3,502.1 $ 2,732.1 Capital Expenditures* $ 458.3 $ 334.5 Free Cash Flow (operating cash flow less capital expenditures)* $ 3,043.8 $ 2,397.6 Number of Associates 63,000 59,000 Total Assets $ 32,941.0 $ 29,949.5 Total Debt $ 5,343.1 $ 5,305.2 Stockholders’ Equity $ 19,083.9 $ 16,971.8 Total Capitalization (total debt plus stockholders’ equity) $ 24,427.0 $ 22,277.0 *from continuing operations Environmental We provide products that help protect our water supply and air quality by serving two primary markets: water quality and retail/commercial petroleum. Our water quality business provides instrumentation and disinfection systems to help analyze and manage the quality of ultra- pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Our retail/commercial petroleum business is a leading worldwide provider of solutions and services focused on fuel dispensing, remote fuel management, point-of- sale systems, payment systems and environmental compliance. 3 Test & Measurement We are a global provider of electronic measurement instruments, professional test tools, thermal imaging and calibration equipment used in electrical and industrial applications.
    [Show full text]
  • EU Top Applicants 2010-2014 Based on Assignees2014 5Yr.Tsv
    EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv table_row ordering_cd 15943 309 13406 105 13407 105 13408 105 13409 105 13410 105 13411 105 13412 105 13413 105 13414 105 13415 105 13416 105 13417 105 13418 105 13419 105 13420 105 13421 105 13422 105 13423 105 13424 105 Page 1 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv st_country_cd us_or_foreign FRX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) Page 2 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv state_country_of_origin assignee_name FRANCE IMERJ, LTD. AUSTRIA INFINEON TECHNOLOGIES AG AUSTRIA ~INDIVIDUALLY OWNED PATENT AUSTRIA AMS AG AUSTRIA NXP B.V. AUSTRIA JULIUS BLUM GMBH AUSTRIA BAXTER INTERNATIONAL INC. AUSTRIA EPCOS AG AUSTRIA INFINEON TECHNOLOGIES AUSTRIA AG AUSTRIA MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH AUSTRIA SIEMENS AKTIENGESELLSCHAFT AUSTRIA AVL LIST GMBH AUSTRIA MAGNA POWERTRAIN AG & CO KG AUSTRIA HILTI AKTIENGESELLSCHAFT AUSTRIA BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUSTRIA FRONIUS INTERNATIONAL GMBH AUSTRIA SIEMENS VAI METALS TECHNOLOGIES GMBH AUSTRIA CONTINENTAL AUTOMOTIVE GMBH AUSTRIA INTEL MOBILE COMMUNICATIONS GMBH AUSTRIA MAGNA STEYR FAHRZEUGTECHNIK AG & CO. KG Page 3 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv CY_2010 CY_2011
    [Show full text]
  • Participant List
    Participant list Please find below a list of current participants in theAustralian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A Menarini Australia Beckman Coulter – Diagnostics Ego Pharmaceuticals AbbVie Australia Beckman Coulter – Life Sciences Elanco Australasia Alcon Becton Dickinson Eli Lilly Australia Allergan Biogen Essilor Australia Alphapharm bioMerieux Australia Evolution Health Amgen Blackmores FarmaForce Arjo Australia Boehringer Ingelheim Ferring Pharmaceuticals Aspen Australia Boston Scientific Int’l BV Fresenius Kabi Australia Astellas Pharma Australia Bristol Myers Squibb Australia Fresenius Medical Care Australia Astrazeneca Cardinal Health Galderma Australia Australian Nuclear Science and Technology Cepheid GE Australia Healthcare Organisation (ANSTO) Cochlear Getinge Australian Pharmaceutical Industries Coloplast Australia Gilead Sciences B Braun Australia CooperVision Australia GlaxoSmithKline Australia B Braun Avitum Australia Device Technologies Aust Grifols Australia Baxter Healthcare Ecolab Hach Bayer Edwards Lifesciences Henry Schein Halas © March 2020 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 Participant list Herbalife Australasia Mayne Pharma Group PerkinElmer Illumina Australia Medtronic Australasia Permobil Australia Implant Direct Merck Australia Pfizer Australia iNova Pharmaceuticals (Australia) Merck Serono Philips Electronics Australia Integrated DNA Technologies (IDT) Merck Sharp & Dohme Australia
    [Show full text]
  • Company Vendor ID (Decimal Format) (AVL) Ditest Fahrzeugdiagnose Gmbh 4621 @Pos.Com 3765 0XF8 Limited 10737 1MORE INC
    Vendor ID Company (Decimal Format) (AVL) DiTEST Fahrzeugdiagnose GmbH 4621 @pos.com 3765 0XF8 Limited 10737 1MORE INC. 12048 360fly, Inc. 11161 3C TEK CORP. 9397 3D Imaging & Simulations Corp. (3DISC) 11190 3D Systems Corporation 10632 3DRUDDER 11770 3eYamaichi Electronics Co., Ltd. 8709 3M Cogent, Inc. 7717 3M Scott 8463 3T B.V. 11721 4iiii Innovations Inc. 10009 4Links Limited 10728 4MOD Technology 10244 64seconds, Inc. 12215 77 Elektronika Kft. 11175 89 North, Inc. 12070 Shenzhen 8Bitdo Tech Co., Ltd. 11720 90meter Solutions, Inc. 12086 A‐FOUR TECH CO., LTD. 2522 A‐One Co., Ltd. 10116 A‐Tec Subsystem, Inc. 2164 A‐VEKT K.K. 11459 A. Eberle GmbH & Co. KG 6910 a.tron3d GmbH 9965 A&T Corporation 11849 Aaronia AG 12146 abatec group AG 10371 ABB India Limited 11250 ABILITY ENTERPRISE CO., LTD. 5145 Abionic SA 12412 AbleNet Inc. 8262 Ableton AG 10626 ABOV Semiconductor Co., Ltd. 6697 Absolute USA 10972 AcBel Polytech Inc. 12335 Access Network Technology Limited 10568 ACCUCOMM, INC. 10219 Accumetrics Associates, Inc. 10392 Accusys, Inc. 5055 Ace Karaoke Corp. 8799 ACELLA 8758 Acer, Inc. 1282 Aces Electronics Co., Ltd. 7347 Aclima Inc. 10273 ACON, Advanced‐Connectek, Inc. 1314 Acoustic Arc Technology Holding Limited 12353 ACR Braendli & Voegeli AG 11152 Acromag Inc. 9855 Acroname Inc. 9471 Action Industries (M) SDN BHD 11715 Action Star Technology Co., Ltd. 2101 Actions Microelectronics Co., Ltd. 7649 Actions Semiconductor Co., Ltd. 4310 Active Mind Technology 10505 Qorvo, Inc 11744 Activision 5168 Acute Technology Inc. 10876 Adam Tech 5437 Adapt‐IP Company 10990 Adaptertek Technology Co., Ltd. 11329 ADATA Technology Co., Ltd.
    [Show full text]
  • Residents Ask Representative Ed Royce to Stand up by Barbara Sobin
    COMMUNITY Fullerto♥ n bsCeALErNDAvR Peage 1r 0-11 O EAR FULLERTON’S ONLY INDEPENDENT NEWS • Est.1978 (printed on 20% recycled paper) • Y 39 #4 • EARLY MARCH 2017 Submissions: [email protected] • Contact: (714) 525-6402 • Read Online at : www.fullertonobserver.com Coyote Hills Nature MAPLE MURAL : Walk March 11 Artist The Friends of Coyote Hills will hold Katherine a Nature Walk in the West Coyote Hills England on March 11 from 9am to 11am. Meet and crew at the Laguna Lake Equestrian Center Sue Ferrante, on Lakeview Drive. Bring water and Aya Kinoshita, wear comfortable shoes. Free. Visit Nancy Francis, www.coyotehills.org for information. Myra Machen Allen, and Grants for Carol Towler, finished West Coyote Hills installing the • $2 million: The San Gabriel and new mural at Lower Los Angeles Rivers Mountains Maple Conservancy announced it has granted Elementary. $2 million toward the acquisition of a The mural was 10.4 acre parcel in West Coyote Hills designed by adjacent to the 72.3 acre Robert E. Maple students Ward Nature Preserve. The grant was and made by made possible by the Water Quality, the All the Arts Supply and Infrastructure Improvement for All the kids Act of 2014 (Prop 1 Water Bond). Foundation • $50,000: The Henry W. and Ellen after school R. Warne Family Endowment Fund, a program 5th grant program of the OC Community grade Master Foundation, announced a $50,000 Mosaics class. grant to the City of Fullerton to assist in Ribbon cutting acquisition of land at West Coyote Hills. is on Visit www.cityoffullerton.com/westcoy - March 10.
    [Show full text]